Skip to main content

Advertisement

Table 1 Summary table on vaccine assumptions

From: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Vaccine assumptions (proportion of exposed people avoiding the infection) HPV 16 HPV 18 HPV 31, 33, 45, 52 and 58
Cervical cancer
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections
 Male* 0.411 0.621 0.411
 Female** 0.76 0.963 0.76
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent 0.988 0.984 0.988
Degree of protection of the vaccine against HPV16/18 -related CIN 0.979 1 0.979
Vaginal and vulvar cancers
Vaccine efficacy for preventing vaginal/vulvar HPV16/18 infections
 Male* 0.411 0.621  
 Female** 0.76 0.963  
Degree of protection of the vaccine against vaginal/vulvar HPV16/18 infections becoming persistent 0.988 0.984  
Degree of protection of the vaccine against HPV16/18-related/VaIN/VIN 1 1  
Anal cancers
Vaccine efficacy for preventing anal HPV16/18 infections
 Male* 0.411 0.621 0.621
 Female** 0.76 0.963 0.963
Degree of protection of the vaccine against anal HPV16/18 infections becoming persistent
 Male* 0.787 0.96 0.96
 Female** 0.988 0.984 0.984
Degree of protection of the vaccine against HPV16/18 -related AIN 0 0 0
Penile and H&N cancers
Vaccine efficacy for preventing anal/penile**/H&N HPV16/18 infections
 Male* 0.411 0.621  
 Female** 0.76 0.963  
Degree of protection of the vaccine against anal/penile/H&N HPV16/18 infections becoming persistent
 Male* 0.787 0.96  
 Female** 0.988 0.984  
Degree of protection of the vaccine against HPV16/18 -related AIN/PIN/H&N neoplasia 0 0  
  1. * Preventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females
  2. ** Preventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males